Terkko Navigator / Annals of the rheumatic diseases

Comment on the 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus by Fanouriakis et al

Hydroxychloroquine dosing in systemic lupus erythematosus: response to 'Comment on the 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus by Fanouriakis et al by Costedoat-Chalumeau et al

Decision-making value of nuclear dense fine speckled pattern in systemic autoimmune rheumatic disease: trick or treat?

Response to 'Decision making value of nuclear dense fine speckled pattern in systemic autoimmune rheumatic disease: trick or treat? by Deng et al

Comorbidity and long-term outcome in patients with congenital heart block and their siblings exposed to Ro/SSA autoantibodies in utero

Effects of maternal medication on long-term outcome in congenital heart block remain to be established. Response to: 'Comorbidity and long-term outcome in patients with congenital heart block and their siblings exposed to Ro/SSA autoantibodies in ute

Comment on: 'Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis by Sabbagh et al

Response to: 'Comment on: 'Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis by Sabbagh S et al by Yang et al

Differentiating disease activity from damage in systemic sclerosis: its still early days!

Response to: 'Differentiating disease activity from damage in systemic sclerosis: its still early days! by Jain and Sharma

Mycophenolate mofetil: a step forward in the induction treatment of ANCA-associated vasculitis? Comment on the article by Jones et al

Response to: 'Mycophenolate mofetil: a step forward in the induction treatment of ANCA-associated vasculitis? Comment on the article by Jones et al by Vandergheynst et al

Analysis of IL-6 measurement in patients with GCA treated with tocilizumab should consider concomitant treatment with prednisone

Longitudinal versus cross-sectional IL-6 measurements in tocilizumab-treated GCA. Response to: 'Analysis of IL-6 measurement in GCA patients treated with tocilizumab should consider concomitant treatment with prednisone by Samson and Bonnotte

Smart battles: immunosuppression versus immunomodulation in the inflammatory RMDs

Kawasaki disease or Kawasaki syndrome?

Eric Bywaters a life story: 1 June 1910 to 2 April 2003

Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort

Clinical features of rheumatic patients infected with COVID-19 in Wuhan, China

Incidence trend of five common musculoskeletal disorders from 1990 to 2017 at the global, regional and national level: results from the global burden of disease study 2017

Adalimumab dose tapering in patients with rheumatoid arthritis who are in long-standing clinical remission: results of the phase IV PREDICTRA study

Mixed methods study of clinicians perspectives on barriers to implementation of treat to target in psoriatic arthritis

Novel and reliable DACTylitis glObal Sonographic (DACTOS) score in psoriatic arthritis

Normal human enthesis harbours conventional CD4+ and CD8+ T cells with regulatory features and inducible IL-17A and TNF expression

Outcomes and treatment responses, including work productivity, among people with axial spondyloarthritis living in urban and rural areas: a mixed-methods study within a national register

MRI of sacroiliac joints for the diagnosis of axial SpA: prevalence of inflammatory and structural lesions in nulliparous, early postpartum and late postpartum women

Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis

Lack of EULAR/ERA-EDTA response at 1 year predicts poor long-term renal outcome in patients with lupus nephritis

Predictive factors for treatment-related mortality and major adverse events after autologous haematopoietic stem cell transplantation for systemic sclerosis: results of a long-term follow-up multicentre study

Canakinumab for Treatment of Adult-Onset Stills Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial

Long-term effectiveness and safety of secukinumab for treatment of refractory mucosal and articular Behcets phenotype: a multicentre study

Does cartilage loss cause pain in osteoarthritis and if so, how much?

TGF{beta} attenuates cartilage extracellular matrix degradation via enhancing FBXO6-mediated MMP14 ubiquitination

Patient discussions of glucocorticoid-related side effects within an online health community forum

Gender disparity in authorship of guidelines and recommendations in rheumatology

Significant weight loss in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database

Successful remission with tofacitinib in a patient with refractory Takayasu arteritis complicated by ulcerative colitis

Tocilizumab in symptomatic calcium pyrophosphate deposition disease: a pilot study

TARA study: a new perspective on tapering drugs in RA

Response to: 'TARA Study: a new perspective on tapering drugs in RA by Mishra et al

Tapering without relapse in rheumatoid arthritis patients with high TNF blocker concentrations: data from STRASS study

Response to: 'Tapering without relapse in rheumatoid arthritis patients with high TNF blocker concentrations: data from the STRASS study by Marotte et al

Interosseous tendon inflammation of rheumatoid arthritis: what's the real meaning?

Response to: 'Interosseous tendon inflammation of rheumatoid arthritis: what's the real meaning? by Deng et al

Comment on: 'Idiopathic inflammatory myopathies and antisynthetase syndrome: contribution of antisynthetase antibodies to improve current classification criteria by Greco et al

Response to: 'Comment on: 'Idiopathic inflammatory myopathies and antisynthetase syndrome: contribution of antisynthetase antibodies to improve current classification criteria by Greco et al by Knitza et al

Antisynthetase antibodies in clinical laboratories: the importance of clinical correlation and indirect immunofluorescence. Response to: Comment on: 'Idiopathic inflammatory myopathies and antisynthetase syndrome: contribution of antisynthetase antib

Can IL-1 be used as a target for osteoarthritis?

Response to: 'Can IL-1 be used as a target for osteoarthritis? by Cheng et al

Hopefulness of 'Hope